Follow-up data from phase 3 trial of pfizer-biontech covid-19 vaccine support safety and high efficacy in adolescents 12 through 15 years of age

New york and mainz, germany, november 22, 2021 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced topline results from a longer-term analysis of the safety and efficacy of their covid-19 vaccine in individuals 12 through 15 years of age. the updated findings from the companies' pivotal phase 3 trial show that a two-dose series of the pfizer-biontech covid-19 vaccine (30-Μg per dose) was 100% effective against covid-19, measured seven days through over four months after the second dose.
BNTX Ratings Summary
BNTX Quant Ranking